Result of WRAP Retail Offer

Physiomics PLC

18 March 2026

 

Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 17 March 2026.

18 March 2026

Physiomics Plc

("Physiomics" or the "Company")

Result of WRAP Retail Offer

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions is pleased to announce, further to the announcements made on 17 March 2026, the completion of the WRAP Retail Offer, at the same issue price as the previously announced Placing (together the "Fundraise"). The WRAP Retail Offer, which closed at midday today, 18 March 2026, has raised aggregate gross proceeds of £110,000.00 through the issue of a total of 27,500,000 new Ordinary Shares at a price of £0.004 per share, alongside the previously announced Placing which raised gross proceeds of £490,000.00.

The Fundraise, which is conditional only on Admission, raised gross proceeds of, in aggregate, £600,000.00, via the issue of 122,500,000 Placing Shares pursuant to the Placing and 27,500,000 WRAP Retail Offer Shares pursuant to the WRAP Retail Offer.

Admission and Total Voting Rights

Applications have been made for the Placing Shares and the WRAP Retail Offer Shares to be admitted to trading on AIM, which is expected to become effective and dealings commence on or around 8.00 a.m. on 20 March 2026 ("Admission").

Following Admission, the Company's issued ordinary share capital will consist of 453,208,718 Ordinary Shares. Since the Company currently holds no Ordinary Shares in treasury, the total voting rights in the Company will be 453,208,718. These figures may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The new Ordinary Shares to be issued pursuant to the WRAP Retail Offer (which is conditional on the Placing) will be issued free of all liens, charges and encumbrances and will, on Admission, rank pari passu in all respects with the new Ordinary Shares to be issued pursuant to the Placing and the Company's existing Ordinary Shares.

For Further Information

Physiomics plc	[phone]
Dr Peter Sargent, CEO
Hybridan LLP (Broker)	[phone]
Claire Louise Noyce
Strand Hanson Limited (NOMAD) James Dance, James Bellman	[phone]
Winterflood Retail Access Platform	[e-mail]
Sophia Bechev, Kaitlan Billings	0203 100 0214

Further information on the Company can be found on its website at www.physiomics.co.uk

The Company's LEI is 213800A71DSZ6ABMTQ91.

 Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.   

 

END